J. Paludo

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
J Paludo, J. Paludo, Jonas C. Paludo, Jonas Paludo
Publication record
326 papers · 2,552 citations · H-index 23

PAPERS

Large Language Model for Abstraction of CAR-T Therapy Toxicities Data
20260 citationsauthor #33
Data Infrastructure to Support IEC Compliance and Research Program
20260 citationsauthor #4
AI Multimodal Large Language Model on CAR-T Pre-Leukapheresis Evaluation to Predict Monitoring Needs Post Infusion for Early Dismissal Planning
20260 citationsauthor #28
Early Integration of Cellular, Molecular, and Bispecific Therapy Education for Nurses
20260 citationsauthor #7
Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).
20260 citationsauthor #7
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.
20260 citationsauthor #14
Modeling Evolving Toxicity Risk after CAR-T with Time-Dependent Hazards
20260 citationsauthor #1
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival
20250 citationsauthor #21
Association of immune cell subsets and cytokine profiles with immune-related hyperinflammatory states after CAR T-cell therapy.
20250 citationsauthor #7
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
20250 citationsauthor #8
Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States
20255 citationsauthor #9
Impact of cell of origin, gene rearrangements, and frontline treatment on incidence of secondary central nervous system lymphoma in newly diagnosed diffuse large B-cell lymphoma.
20250 citationsauthor #5
Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma
20250 citationsauthor #7
Treatment selection preferences and barriers in relapsed or refractory large B-cell lymphoma.
20250 citationsauthor #6
Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy
20250 citationsauthor #1
Administration of tarlatamab in an outpatient setting utilizing remote patient monitoring: Mayo Clinic experience.
20250 citationsauthor #6
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
202521 citationsauthor #7
A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era
20250 citationsauthor #6
Telehealth utilization in neuro-oncology: A single institution experience.
20250 citationsauthor #17
Anatomical localization-based analysis of de novo secondary cns lymphoma
20250 citationsauthor #9
Clinical Cytokine Assays Early in the Course of Cytokine Release Syndrome (CRS) after CAR-T Therapy Show Difference Among Patients with Severe CRS Versus Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS)
20250 citationsauthor #10
POSTER: ABCL-1172 High Incidence of Central Nervous System Relapse in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
20250 citationsauthor #17
Genetic evolution of Waldenström macroglobulinemia across disease stages
20250 citationsauthor #4
Machine learning-based prediction of cytokine release syndrome post CAR-T cell therapy.
20251 citationsauthor #1
Enhancing educational experiences through standardization of inpatient hematology curriculums.
20250 citationsauthor #4
Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma
20250 citationsauthor #15
Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up
20250 citationsauthor #2
Machine learning analysis of continuous body temperature data to differentiate between infectious and non-infectious fevers in bone marrow transplant recipients.
20250 citationsauthor #7
The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma
20250 citationsauthor #8
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
20254 citationsauthor #1
Large language model for abstraction of CAR-T therapy toxicities data
20250 citationsauthor #29
Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)
20250 citationsauthor #12
Impact of pre-lymphodepletion (pre LD) and day 30 (M1) immune cell counts on outcomes of CAR T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
20250 citationsauthor #5
Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma
20250 citationsauthor #14
AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning
20250 citationsauthor #28
Reassessing pre-chemotherapy laboratory testing in R-CHOP: Are we doing too much?
20250 citationsauthor #8
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia.
20250 citationsauthor #2
Clinics and clicks: Understanding hematology healthcare delivery utilization and preferences in the digital era
20250 citationsauthor #7
The hidden toll: Defining impacts of home call on oncology fellows.
20250 citationsauthor #6
Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia
20241 citationsauthor #7
Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
20242 citationsauthor #13
The Growing Role of Digital Health Tools in the Care of Patients with Cancer: Current Use, Future Opportunities, and Barriers to Effective Implementation
202410 citationsauthor #2
Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy
20246 citationsauthor #8
Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways
20240 citationsauthor #2
Autologous stem cell transplant in fit patients with late relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
20242 citationsauthor #8
Metformin and cytokine release syndrome after immune effector cell therapy.
20240 citationsauthor #19
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity
20241 citationsauthor #8
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
20241 citationsauthor #4
Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies
20243 citationsauthor #7
Distinguishing Infection- Vs. Non-Infection-Related Febrile Neutropenia in HCT Patients By Machine Learning Analysis of Continuous Body Temperature Data Collected Using a Wearable Sensor
20241 citationsauthor #8
Abstract 3841: Tumor-derived microRNA125a induces CART cell apoptosis and failure in B cell malignancies
20240 citationsauthor #19
Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
20240 citationsauthor #4
Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
20240 citationsauthor #9
Metformin and Cytokine Release Syndrome after Immune Effector Cell Therapy
20242 citationsauthor #19
MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY AFTER NINE MONTHS OF FOLLOW-UP: A RETROSPECTIVE COHORT STUDY
20240 citationsauthor #7
High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
20245 citationsauthor #6
Abstract 53: T-cell receptor repertoire changes associated with clinical response in patients with B-cell non-Hodgkin’s lymphoma receiving CD19 CAR-T therapy
20240 citationsauthor #13
Serial Evaluation of Pre-immunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.
20243 citationsauthor #8
Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy
20241 citationsauthor #9
Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma
20241 citationsauthor #2
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
20248 citationsauthor #7
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
202415 citationsauthor #11
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
202417 citationsauthor #9
Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas
20241 citationsauthor #6
Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)
20240 citationsauthor #6
Remote Patient Monitoring to Transform Management of Febrile Neutropenia in Cancer Patients
20249 citationsauthor #2
Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
20241 citationsauthor #6
Call Me Maybe: An Analysis of Hematology Fellowship Home-Call Burden, Perceptions, and Attitudes
20240 citationsauthor #5
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy
20242 citationsauthor #13
Abstract 4001: Monocyte transcriptome profiles associated with clinical response in patients with B-cell non-Hodgkin’s lymphoma receiving CD19-directed CAR-T therapy
20240 citationsauthor #12
Understanding fellow hematology curriculums: Characterizing perspectives and defining opportunities for improvement.
20240 citationsauthor #4
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.
20243 citationsauthor #2
The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma
20230 citationsauthor #16
IS SYSTOLIC AND DIASTOLIC FUNCTION INCLUDING GLOBAL LONGITUDINAL STRAIN BY ECHOCARDIOGRAPHY COMPROMISED IN ADULT PATIENTS TREATED WITH CD19 CAR T-CELL THERAPIES FOR HEMATOLOGICAL MALIGNANCIES IN THOSE THAT DEVELOPED CYTOKINE RELEASE SYNDROME?
20230 citationsauthor #6
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
202321 citationsauthor #9
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
20239 citationsauthor #13
Day 100 Natural Killer Cell/CD14+HLA‐DRDIM ratio and survival in lymphoma post‐autologous peripheral blood hematopoietic stem cell transplantation
20233 citationsauthor #6
Care utilization and satisfaction among patients with cancer with neutropenic fever managed by a remote patient monitoring (RPM) program.
20232 citationsauthor #2
Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities
202319 citationsauthor #3
Patient- and Provider-Level Factors Associated With Telehealth Utilization Across a Multisite, Multiregional Cancer Practice From 2019 to 2021
202312 citationsauthor #13
Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program
20234 citationsauthor #1
Treatment Pattern and Survival Outcome of Limited Stage Mantle Cell Lymphoma: A National Cancer Database Analysis in Pre-BTK Inhibitor Vs BTK Inhibitor Era
20230 citationsauthor #4
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
20238 citationsauthor #9
Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas
20234 citationsauthor #13
Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin Lymphoma.
20231 citationsauthor #11
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory and early relapsing diffuse large B-cell lymphoma (DLBCL).
20230 citationsauthor #8
Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis
20230 citationsauthor #12
Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia
20230 citationsauthor #3
A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group
20232 citationsauthor #7
Autologous Stem Cell Transplant in Fit Patients with Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy
20231 citationsauthor #8
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
20237 citationsauthor #2
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
202314 citationsauthor #26
Day 100 Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cell Receptors Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas
20231 citationsauthor #6
P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
20234 citationsauthor #12
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
202321 citationsauthor #8
Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Waldenström Macroglobulinemia Initiating First-Line Treatment with Ibrutinib or Zanubrutinib
20231 citationsauthor #1
Outcomes in Mantle Cell Lymphoma with Central Nervous System Involvement - a Dual Center Study
20233 citationsauthor #22
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
202319 citationsauthor #9
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience
20232 citationsauthor #4
Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
20235 citationsauthor #2

TIMELINE

2013 6 citations

2014 82 citations

2015 48 citations

2016 93 citations

2017 77 citations

2018 649 citations

2019 294 citations

2020 128 citations

2021 373 citations

2022 355 citations

2023 337 citations

2024 95 citations

2025 31 citations

2026 0 citations

Unknown 0 citations

J. Paludo

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT